Search Results 731-740 of 18365 for alopecia

1. Mayo Clinic Q and A: Cold cap therapy can reduce hair loss caused by chemotherapy

   DEAR MAYO CLINIC: How effective is cold cap therapy in preventing hair loss in people undergoing chemotherapy treatments? Are there any risks?

2. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   ... alopecia, oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities, and other non-clinically significant adverse events. - Any of the ...

3. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

   ... alopecia and oxaliplatin induced neurotoxicity ≤ grade 2; Albumin levels > 2.5; Any of the following: Pregnant women; Nursing women; Men or women of ...

4. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

   Note: Subjects with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study. Note: If subjects ...

5. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol) - Mayo Clinic

   Acute effects of any prior therapy resolved to baseline severity or to Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 (except for alopecia, ...

6. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   ... alopecia and peripheral sensory neuropathy. - Subjects of childbearing potential agree to use two forms of medically approved contraception while taking the ...

7. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

8. A Study to Test the Addition of berzosertib to Usual Radiation Treatment for Chemotherapy-Resistant Breast Cancer - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia ...

9. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study - Mayo Clinic

   ... alopecia or vitiligo). PRE-REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to pre-registration) (Must be >= 7 days after most recent ...

10. Safusidenib Phase 2 Study In IDH1 Mutant Glioma - Mayo Clinic

    conditions such as alopecia, temozolomide-induced lymphopenia and irreversible changes associated with radiation therapy). 12. Female patients who engage in ...